Quick Answer
Tonix Pharmaceuticals Holding Corp. reported Cash and Equivalents of $207.64 million for fiscal year 2025.
Tonix Pharmaceuticals Holding Corp. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $207.64M | +110.2% |
| 2024 | $98.78M | +295.9% |
| 2023 | $24.95M | -79.2% |
| 2022 | $120.23M | -32.7% |
| 2021 | $178.66M | +131.8% |
| 2020 | $77.07M | +585.1% |
| 2019 | $11.25M | -55.1% |
| 2018 | $25.03M | -1.8% |
| 2017 | $25.50M | +34.6% |
| 2016 | $18.94M | -1.2% |
| 2015 | $19.18M | -49.8% |
| 2014 | $38.18M | +365.5% |
| 2013 | $8.20M | +359.5% |
| 2012 | $1.78M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $190.06M | +573.2% | +51.6% |
| June 30, 2025 | $125.33M | +2915.7% | -4.8% |
| March 31, 2025 | $131.72M | +1768.6% | +33.3% |
| December 31, 2024 | $98.78M | +295.9% | +249.9% |
| September 30, 2024 | $28.23M | +308.3% | +579.3% |
| June 30, 2024 | $4.16M | -83.8% | -41.0% |
| March 31, 2024 | $7.05M | -90.2% | -71.7% |
| December 31, 2023 | $24.95M | -79.2% | +260.8% |
- Tonix Pharmaceuticals Holding Corp. showed an increase of +110.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2012–2025 period, Tonix Pharmaceuticals Holding Corp.’s cash and equivalents has grown by 11532.3% (from $1.78 million to $207.64 million).
- The most recent figure is from Tonix Pharmaceuticals Holding Corp.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: